Trial Profile
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jul 2022
Price :
$35
*
At a glance
- Drugs Rivogenlecleucel (Primary) ; Rimiducid
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Bellicum Pharmaceuticals
- 10 Jul 2022 Planned End Date changed from 1 Nov 2032 to 1 Oct 2032.
- 01 Oct 2020 Planned End Date changed from 1 Dec 2033 to 1 Nov 2032.
- 24 Oct 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2033.